[
  {
    "ts": null,
    "headline": "Regeneron Upgraded as AbbVie Catches Policy Heat",
    "summary": "Citi sees MFN pricing and PBM threats as manageable for REGN but riskier for ABBV",
    "url": "https://finnhub.io/api/news?id=08a6e49d62891654fec8e67d25d9c0070472bb525cb9b0f0e9ffdf6d9a5fe079",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747263764,
      "headline": "Regeneron Upgraded as AbbVie Catches Policy Heat",
      "id": 134460780,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Citi sees MFN pricing and PBM threats as manageable for REGN but riskier for ABBV",
      "url": "https://finnhub.io/api/news?id=08a6e49d62891654fec8e67d25d9c0070472bb525cb9b0f0e9ffdf6d9a5fe079"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.",
    "summary": "Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen next.",
    "url": "https://finnhub.io/api/news?id=f8c1cfa894866d555966a99ef25ad5025cc94366a9494d7fb939373c94d2bfdc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747232640,
      "headline": "Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.",
      "id": 134460785,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen next.",
      "url": "https://finnhub.io/api/news?id=f8c1cfa894866d555966a99ef25ad5025cc94366a9494d7fb939373c94d2bfdc"
    }
  }
]